Dermatofibrosarcoma Protuberans (DFSP) is treated within the GW Cancer Center's Cutaneous Oncology Program. DFSPs are a locally aggressive soft tissue tumor considered an intermediate-to-low grade malignancy with a high recurrence rate.
- DFSPs originate from the connective tissue and are most often due to a chromosomal mutation.
- DFSPs rarely metastasis, but often can be large and deep, frequently involving muscle or deeper structures.
- Lesions are typically firm, somewhat scar-like plaques or nodules with a pink to reddish-brown color.
- Mohs surgery is generally the best treatment option, providing the highest cure rates for these highly recurrent rare tumors.
Dermatofibrosarcoma Protuberans is treated within the GW Cutaneous Oncology Program
- Comprehensive Skin Cancer and Supportive Oncodermatology Services
The GW Cancer Center's Cutaneous Oncology Program is a leading comprehensive melanoma and non-melanoma skin cancer treatment center in Washington, D.C. Every skin cancer is different, and as a result, we take an individualized approach to each skin cancer patient. Our multidisciplinary team includes specialists in medical and surgical dermatology, head and neck surgery, plastic surgery, medical oncology, radiation oncology, dermatopathology, and genetic counseling. Our team works closely together to offer patients the most personalized treatment plan for their skin cancer, no matter how common, rare or complex. Together, your team will develop a treatment plan tailored to your disease, your concerns, and your lifestyle considerations.
Cutaneous Oncology Program Information
The GW Cancer Center's Cutaneous Oncology program oversees the care of patients with all types of active skin cancers, as well as patients with suspected skin cancers who are in need of diagnostic testing or surveillance. Skin cancers are more common than all other cancers combined, and the incidence of skin cancers is rising faster than any other type of cancer. The Cutaneous Oncology Program provides highly specialized care for all types of skin cancer.
We also provide care for patients experiencing skin-related side effects from any type of cancer or its treatment through our Supportive Oncodermatology Clinic, including:
- Skin reactions to cancer chemotherapy
- Skin reactions to radiation therapy
- Hair or nail changes due to cancer chemotherapy
- Graft-versus-host disease (GVHD)
Our personalized and multidisciplinary approach allows patients to have access to a wide variety of physicians during their visit, including:
- Dermatologists evaluate and monitor suspicious lesions and help to manage the side effects of chemotherapy and radiation therapy
- Dermatopathologists evaluate tissue slides of possible cancerous lesions
- Dermatologic surgeons and surgical oncologists work together to most effectively remove malignant lesions using cutting edge surgical therapies like Mohs micrographic surgery
- Radiation oncologists add radiation therapy to bolster cure rates
- Medical oncologists add chemo and immunotherapy to treat more advanced skin cancers
- Genetic counselors help patients understand and manage their risk for cancer
Our program is broken into four specialized weekly multidisciplinary clinics which include:
Approach to Treatment
You will be cared for by a comprehensive team that combines leading experts with the latest technological and research advances. Our multidisciplinary team works together to create a personalized treatment plan that supports all of your medical, nutritional and emotional needs. At the GW Cancer Center's Cutaneous Oncology Program, you will have access to:
- A multidisciplinary treatment team of world-renowned experts in dermatologic oncology, dermatologic and Mohs surgery, dermatopathology, head and neck surgery, reconstructive surgery, radiation oncology, medical oncology and radiology
- Clinical trials
- Advanced radiation oncology techniques including external beam radiation therapy (EBRT), intensity modulated radiation therapy (IMRT) and surface mold computer-optimized high-dose-rate bracytherapy (SMBT)
- Mohs Surgery, including using immunostains for Melanoma, Merkel Cell Carcinoma and other aggresive or rare skin cancers.
Skin Cancer Information for Patients
Skin cancers are more common than all other cancers combined. The incidence of skin cancers is also rising faster than any other cancer. Skin cancers can include:
- Basal Cell Carcinoma (BCC)
- Squamous Cell Carcinoma (SCC)
- Merkel Cell Carcinoma (MCC)
- Dermatofibrosarcoma Protuberans (DFSP)
- Cutaneous T-cell and B-cell lymphoma (CTCL, CBCL)
- Rare cutaneous adnexal neoplasms (such as eccrine, apocrine, or sebaceous carcinomas and hair follicle tumors)
- Other rare skin cancers
Research and Clinical Trials
The GW Cancer Center's Cutaneous Oncology Program offers a variety of clinical trials. Patients can also enroll in our blood, tissue and database collection studies for melanoma, squamous cell carcinoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. For more information about enrolling in a clinical trial or collection study, please contact Janene Herring, Cutaneous Oncology Program coordinator at (202) 741-2829 or email firstname.lastname@example.org.
Mohs Micrographic Surgery (MMS)
Developed in the 1940s by Dr. Frederic Mohs, MMS is an outpatient procedure that involves surgically removing the visible tumor, along with a thin layer of normal-appearing tissue around and beneath the tumor.
Cutaneous Oncology in the News
- Deciding When to Perform Mohs: Q&A with Drs. Konda and Patel (The Dermatologist, February 2020)
- Sharp Declines for Lung Cancer, Melanoma Deaths Fuel Record Drop in Cancer Mortality (MD Edge Dermatology, January 2020)
- Melanoma Can Happen Anywhere: A Doctor First Thought it was an Ingrown Hair (Today Show, October 2019)
- Skin Cancer Screening: Free Events May Fall Short (Oncology Times, September 2019)
- GW Cancer Center Selected as First Site to Open for Clinical Trial in Patients with High Risk Cutaneous Squamous Cell Carcinoma (July 2019)
- Members of the GW Cancer Center's Cutaneous Oncology Program contributed content to ACCC's Multidisciplinary Advanced Cutaneous Squamous Cell Carcinoma Care (August 2019)
- Skin Safety Gap Divides White, Older from Nonwhite, Younger ( MD Edge Dermatology, July 2019)
Page last updated: July 2019